Download Guideline - Rotherham CCG

NHS Rotherham Clinical Commissioning Group
Framework of NICE Guidance
Dec 2015
Guideline
No
TA369
TA370
Title
Summary
Implications & Action
Ciclosporin for treating dry
eye disease that has not
improved despite
treatment with artificial
tears
Ciclosporin (Ikervis) is recommended as a possible treatment for
people with dry eye disease that has not improved despite treatment
with artificial tears.
Ciclosporin is recommended
as an option, within its
marketing authorisation, for
treating severe keratitis in
adult patients with dry eye
disease that has not
improved despite treatment
with tear substitutes.
Bortezomib for previously
untreated mantle cell
lymphoma
What does this mean for me?
If you have severe dry eye disease that has not improved despite
treatment with artificial tears, and your doctor thinks that ciclosporin is
the right treatment, you should be able to have the treatment on the
NHS.
Ciclosporin should be available on the NHS within 3 months of the
guidance being issued.
Bortezomib (Velcade) is recommended as a possible treatment for
adults with mantle cell lymphoma that has not been treated before, if
haematopoietic stem cell transplantation is not suitable for them.
Completed Actions
The guidance recommends
ciclosporin as an option for
treating severe keratitis in
adult patients with dry eye
disease that has not
improved despite treatment
with tear substitutes.
This would be an option for
treatment to be initiated in
secondary care. Rotherham
CCG would accept
prescribing costs after that.
NHSE is the responsible
commissioner for this drug.
What does this mean for me?
If you have mantle cell lymphoma, and your doctor thinks that
bortezomib is the right treatment, you should be able to have the
treatment on the NHS.
Bortezomib should be available on the NHS within 3 months of the
guidance being issued.
TA371
Trastuzumab emtansine for
treating HER2-positive,
unresectable locally
840986272
Trastuzumab emtansine (Kadcyla) is not recommended. This drug
is for adults with advanced HER2-positive breast cancer that has
been treated before with trastuzumab and a taxane (paclitaxel or
N/A
1
NHS Rotherham Clinical Commissioning Group
Framework of NICE Guidance
Dec 2015
Guideline
No
TA372
Title
Summary
advanced or metastatic
breast cancer after
treatment with trastuzumab
and a taxane
docetaxel).
Apremilast for treating
active psoriatic arthritis
Apremilast (Otezla) is not recommended for adults with active
psoriatic arthritis when earlier treatment with disease-modifying
antirheumatic drugs (DMARDS) has not worked well enough or isn’t
suitable.
Implications & Action
Completed Actions
What does this mean for me?
If you are already taking trastuzumab emtansine you should be able
to continue taking it until you and your doctor decide it is the right time
to stop.
n/a
What does this mean for me?
If you are already taking apremilast for psoriatic arthritis, you should
be able to continue taking it until you and your doctor decide it is the
right time to stop.
TA373
Abatacept, adalimumab,
etanercept and tocilizumab
for treating juvenile
idiopathic arthritis
Abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel) and
tocilizumab (RoActemra) are recommended as possible treatments
for people with polyarticular juvenile idiopathic arthritis.
Adalimumab and etanercept are recommended as possible
treatments for people with enthesitis-related juvenile idiopathic
arthritis.
Etanercept is recommended as a possible treatment for people with
psoriatic juvenile idiopathic arthritis.
It is unlikely that the
guidance will result in a
significant change in
resource use in the NHS
because it is considered that
the recommendations are
consistent with current
clinical practice.
Commissioning: NHS
England.
What does this mean?
If your (or your child’s) doctor thinks that abatacept, adalimumab,
etanercept or tocilizumab are the right treatment, you (or your child)
should be able to have the treatment on the NHS.
Abatacept, adalimumab, etanercept and tocilizumab should be
available on the NHS within 3 months of the guidance being issued.
840986272
2
NHS Rotherham Clinical Commissioning Group
Framework of NICE Guidance
Dec 2015
Guideline
No
Title
Summary
Implications & Action
Completed Actions
If you (or your child) are not eligible for treatment as described above,
you (or your child) should be able to continue taking abatacept,
adalimumab, etanercept or tocilizumab until you and your (or your
child’s) doctor decide it is the right time to stop.
This guidance replaces NICE technology appraisal guidance on the
use of etanercept for the treatment of juvenile idiopathic arthritis
(TA35).
TA374
Erlotinib and gefitinib for
treating non-small-cell lung
cancer that has progressed
after prior chemotherapy
Erlotinib (Tarceva) is recommended as a possible treatment for
people with locally advanced or metastatic non‑small‑cell lung
cancer that has already been treated with non-targeted chemotherapy
because of delayed confirmation of epidermal growth factor receptor
tyrosine kinase (EGFR‑TK) mutation status, if:
NHSE is the responsible
commissioner for these
drugs.
•their cancer tests positive for the EGFR‑TK mutation or
•it is not known if the cancer is EGFR‑TK mutation‑positive because
of problems with the test, and
- the cancer is very likely to be EGFR‑TK mutation‑positive
- it responds to the first 2 cycles of treatment with erlotinib.
Erlotinib is not recommended for treating locally advanced or
metastatic non‑small‑cell lung cancer that doesn’t test positive for the
EGFR‑TK mutation.
Gefitinib (Iressa) is not recommended for treating non‑small‑cell lung
cancer that has progressed after chemotherapy.
What does this mean for me?
If you have EGFR‑TK positive or unknown non‑small‑cell lung
cancer that has already been treated with non‑targeted
chemotherapy because of delayed confirmation of EGFR status, and
your doctor thinks that erlotinib is the right treatment, you should be
able to have the treatment on the NHS.
840986272
3
NHS Rotherham Clinical Commissioning Group
Framework of NICE Guidance
Dec 2015
Guideline
No
Title
Summary
Implications & Action
Completed Actions
Erlotinib should be available on the NHS within 3 months of the
guidance being issued.
If you are already taking erlotinib or gefitinib for non‑small‑cell lung
cancer, that is not recommended above, you should be able to
continue taking it until you and your doctor decide it is the right time to
stop.
840986272
4